Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Jul 16, 2024
Market Access
Drug rationing coming to Part D
IRA’s restructuring of cost-sharing in the catastrophic phase could force plans to restrict utilization
BioCentury | May 10, 2023
Deals
May 9 Quick Takes: Roche taps Zion for brain-penetrating HER2 program
Plus: Gilead acquires XinThera, Amgen partners with TScan and updates from Ascend, Novavax, Gilead and more
BioCentury | Oct 28, 2022
Product Development
Oct. 28 Quick Takes: Gilead returns to $100B market cap on strong earnings
Plus: vaccines stand out for Sanofi, and updates from Outlook, PTC, Y-mAbs, Ascletis, Agios and more
BioCentury | Feb 2, 2022
Product Development
Heightened anticipation for Trodelvy readout as Gilead builds sales staff
Pair of survival measurements, now expected in March, could lead to label expansion for Gilead’s ADC
BioCentury | Sep 29, 2021
Product Development
Sept. 28 Quick Takes: Quick decision for Comirnaty with Marks at helm?
Plus Biogen, Eisai seeking approval of lecanemab for Alzheimer’s, Transcenta IPO, ViiV, Innovent-Union and more
BioCentury | May 19, 2020
Product Development
May 18 Quick Takes: ChemoCentryx’s Phase II miss; plus Teva, Zai-Novocure, Lava-J&J, Sanofi, Rhythm, ViiV
BioCentury | Feb 21, 2020
Product Development
Feb. 20 Product Development Quick Takes: Priority Review puts BioMarin on track to score first hemophilia gene therapy approval in U.S.; plus Gilead-CDC, Genfit
BioCentury | Jan 25, 2020
Company News
Jan. 24 Company Quick Takes: Tecentriq misses in bladder cancer; plus Gilead-CDC and PureTech
BioCentury | Nov 7, 2019
Politics & Policy
Gilead to seek pause in U.S. government HIV PrEP suit until patent office rules on patent validity
BioCentury | Oct 9, 2019
Politics, Policy & Law
Long-term data help two drugs sway ICER in drug price report
How long-term data helped justify Revlimid, Genovya price increases to ICER where other drugs faltered
Items per page:
1 - 10 of 503